|
Drug Brand Name UROLOGIC SOLUTION G ACTIGALL URSODIOL DEPAKENE VALPROATE SODIUM VALPROIC ACID DEPAKENE VALPROIC ACID VANCOCIN HCL VANCOCIN HCL VANCOCIN HCL VANCOLED VANCOLED VANCOMYCIN HCL VANCOMYCIN HCL VANCOMYCIN HCL PITRESSIN VASOPRESSIN NORCURON VECURONIUM BROMIDE VECURONIUM BROMIDE CALAN CALAN CALAN CALAN SR CALAN SR CALAN SR ISOPTIN ISOPTIN S.R. ISOPTIN S.R. ISOPTIN S.R. VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERELAN VERELAN VERELAN VINBLASTINE SULFATE VINCRISTINE SULFATE VINORELBINE TARTRATE NATAFOLIC BEROCCA B-PLEX FORMULA-B KEY-PLEX NUTRIJECT THEROBEC VI-CERT C1000 WITH B12 VITAPLEX VITAROCA B-JECT-100 L-TONIC AQUASOL E AQUAVIT-E VITAMIN E COUMADIN COUMADIN COUMADIN COUMADIN COUMADIN COUMADIN COUMADIN COUMADIN COUMADIN WARFARIN SODIUM GCN - Generic Drug Description UROLOGIC SOLUTION-G URSODIOL URSODIOL VALPROATE SODIUM VALPROATE SODIUM VALPROATE SODIUM VALPROIC ACID VALPROIC ACID VANCOMYCIN HCL VANCOMYCIN HCL VANCOMYCIN HCL VANCOMYCIN HCL VANCOMYCIN HCL VANCOMYCIN HCL VANCOMYCIN HCL VANCOMYCIN HCL VASOPRESSIN VASOPRESSIN VECURONIUM BROMIDE VECURONIUM BROMIDE VECURONIUM BROMIDE VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VINBLASTINE SULFATE VINCRISTINE SULFATE VINORELBINE TARTRATE VIT B-COMP W-FE, CA, FA 1MG VITAMIN B COMP W-C VITAMIN B COMP W-C VITAMIN B COMP W-C VITAMIN B COMP W-C VITAMIN B COMP W-C VITAMIN B COMP W-C VITAMIN B COMP W-C VITAMIN B COMP W-C VITAMIN B COMP W-C VITAMIN B COMPLEX VITAMIN B COMPLEX VITAMIN E VITAMIN E VITAMIN E WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM Drug Strength Dosage Dose Form Description Description 300MG 250MG ML 250MG 5ML 250MG UNIT ML 20 UNIT ML 10MG 20MG ML 120MG 180MG 240MG ML 2.5MG ML 2.5MG ML 240MG 360MG ML 10MG ML IRRIG SOLN CAPSULE CAPSULE SYRUP VIAL SYRUP CAPSULE CAPSULE VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL TABLET TABLET TABLET TABLET SA TABLET SA TABLET SA VIAL TABLET SA TABLET SA TABLET SA CAP24H PEL TABLET TABLET SA CAP24H PEL TABLET SA AMPUL DISP SYRIN VIAL CAP24H PEL TABLET SA CAP24H PEL TABLET TABLET CAP24H PEL CAP24H PEL CAP24H PEL VIAL VIAL VIAL SYRUP TABLET TABLET TABLET VIAL VIAL TABLET VIAL TABLET TABLET VIAL DROPS DROPS DROPS TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET.
Non-systematic review Non-systematic review Neoadjuvant therapy Laboratory-based study Laboratory-based study Not all participants had ABC 75 had stage II and 29 had stage III breast cancer ; Neoadjuvant therapy Non-systematic review A discussion paper about a study conducted by other researchers see Ibrahim et al., 200157 in included studies section of this review ; that was presented at a conference Ibrahim et al., 1995202 ; Non-systematic review 19 27 received first-line chemotherapy for ABC, but the results were not presented separately. These were interim results that only included 13 evaluable participants Neoadjuvant therapy locally ABC ; Not stated if first- or second-line chemotherapy for ABC Neoadjuvant therapy locally ABC ; Laboratory-based study Overview with no separate data for first-line therapy for breast cancer Dose-escalating study. Not stated if first- or second-line therapy for MBC Second-line therapy for MBC Second-line chemotherapy for MBC. Study compares the use of docetaxel with vinorelbine plus paclitaxel, but not reported to be randomised continued!
To obtain credit: Answer the test questions at the end of this lesson and complete the evaluation online at retailclinician . A certificate of completion will be available to print after achieving 70 percent on the post test and completion of the course evaluation online. Questions regarding statements of credit should be directed to W. Lane Edwards Jr. at Lane 4healtheducation . This lesson is available free of charge to retail clinicians.
Items of note for the NOVEMBER 2007 Release Duplicate concepts. A number of duplicate concepts were inadvertently added to the October 2007 Read Drugs release. These Read codes have now been marked with an asterisk at the start of the 30 character term to indicate the non-availability of these products. The affected Read codes are pNEu., pNEv., pNEw., pNEx., pNG2., pNG3., pNG4. and pNG5. Changed names The names of n4s1. and n4s3. have been changed to accommodate the authoring of a new concept, n4s5. PHASED WITHDRAWAL FROM READ CODE DRUG AND APPLIANCE DICTIONARY.
TABLE 6. FDA-Approved Regimens for the Treatment of Advanced NSCLC Paclitaxel 135 mg m2 over 24 h every three weeks Cisplatin 75 mg m2 after paclitaxel every three weeks Vinorelbine 30 mg m2 weekly Cisplatin 120 mg m2 days 1 and 19, then every six weeks Gemcitabine 1000 mg m2 days 1, 8, and 15 every four weeks Cisplatin 100 mg m2 after gemcitabine day 1 Gemcitabine 1250 mg m2 days 1 and 8 every three weeks Cisplatin 100 mg m2 after gemcitabine day 1 Docetaxel 75 mg m2 day 1 every three weeks Cisplatin 75 mg m2 day 1 every three weeks While the FDA-approved regimens all contain cisplatin, carboplatin is frequently substituted. Carboplatin is more consistent than cisplatin in meeting one of the primary goals of treatment for advanced disease: palliation of symptoms. It is important to consider with cisplatin that even when nausea and vomiting are well controlled, it is still associated with potentially life-threatening side effects such as nephrotoxicity and quality-of-life-affecting side effects such as neurotoxicity or ototoxicity Ginsberg et al., 2001; Miaskowski & Viele, 1999 ; . In addition, the hydration requirements of cisplatin make it inconvenient to administer, particularly in the outpatient setting. To date, none of the third-generation two-drug combination regimens has shown clear benefits over the others in terms of efficacy or toxicity.The various combinations used in advanced NSCLC include paclitaxel-, docetaxel-, vinorelbine-, gemcitabine-, and irinotecan-based platinum regimens, as well as non-platinum two-drug regimens. Paclitaxel-based regimens Combinations containing paclitaxel have been evaluated in a number of clinical trials. In an early multi-institutional registration trial by the Eastern Cooperative Oncology Group ECOG ; , the third-generation regimen of paclitaxel plus cisplatin was compared with the second-generation regimen of etoposide plus cisplatin. Five hundred ninetynine patients who had received no prior chemotherapy were randomized to receive either paclitaxel at one of two different doses 135 mg m2 and 250 mg m2 ; or etoposide 100 mg m2 on days 13. Both sets of patients received cisplatin 75 mg m2, and both regimens were repeated every three weeks.The paclitaxel group showed a longer median survival 9.9 months versus 7.6 months ; and greater oneyear survival 38.9% versus 31.8% ; .This difference was not statistically significant, although the small size of the difference may have been due to longer-than-expected survival times for the etoposide group.Toxicity was higher in the paclitaxel arm, with increased neutropenia at the lower dose and increased myalgias, neurotoxicity, and possibly treatment-related cardiac events in patients receiving the higher dose. Quality of life QOL ; scores, however, were not significantly different in the two arms Bonomi et al., 2000 ; . An additional trial comparing paclitaxel 175 mg m2 and.
Biganzoli, Martin, Twelves The safety profile in both studies was similar to that observed in the capecitabine docetaxel study [1]. Hand-foot syndrome and gastrointestinal adverse events were the predominant toxicities. Most adverse events were mild: the incidence of grade 4 toxicities was very low, and the incidence of grade 3 hand-foot syndrome was 10% [13, 14]. Clearly, the taxanes provide an attractive combination partner for capecitabine, and mature results from these trials are awaited with interest. CAPECITABINE PLUS VINORELBINE COMBINATION THERAPY Vinorelbine is active in MBC and is frequently used in combination with 5-FU. In an ongoing, phase I dose-finding study, 40 patients with pretreated MBC are receiving 21-day treatment cycles of capecitabine 500-1, 250 mg m2 twice daily on days 1-14 ; plus vinorelbine 12.5-22.5 mg m2 on days 1 and 3 ; [15]. Nine dose levels have been evaluated, and the maximum tolerated dose has not been reached. Grade 3 4 neutropenia has been observed in 32% of cycles, and since antitumor activity has been seen at all dose levels, the investigators have decided not to increase doses further. Objective responses so far have been observed in 16 of 48% ; evaluable patients [15]. In a second phase I study, patients with anthracycline taxane-pretreated metastatic disease are also receiving 21-day treatment cycles of capecitabine plus vinorelbine [16]. In that study, the regimens are capecitabine 1, 000 or 1, 250 mg m2 twice daily on days 1-14, plus vinorelbine 25 or 30 mg m2 on days 1 and 8. On the basis of data obtained from the 14 patients evaluated to date, the recommended dose is capecitabine 1, 000 mg m2, plus vinorelbine 25 mg m2. Objective responses have currently been observed in five of nine 56% ; evaluable patients [16]. At the recommended dose level, one dose-limiting toxicity grade 4 neutropenia ; was observed in six patients. Capecitabine vinorelbine combination therapy appears feasible and active and is being evaluated in different settings at the recommended dose of vinorelbine 25 mg m2, plus capecitabine 1, 000 mg m2, twice daily, days 1-14 every 21 days. CAPECITABINE IN ANTHRACYCLINE-CONTAINING COMBINATION THERAPIES Capecitabine has also been evaluated as a component of triple combinations. The primary rationale for combining capecitabine with anthracycline-based regimens is the absence of overlapping toxicities of the two agents. In a phase I study, capecitabine 750-1, 200 mg m2 twice daily on days 1-14 ; given in a 21-day cycle in combination with epirubicin 100 mg m2 on day 1 ; and cyclophosphamide 600 mg m2 on day 1 ; CEX ; was investigated in 23 patients and viracept.
Figure 1.1 Lifelong learning systems in relation to individuals, social systems and society.
Total serum AP was assayed by a kinetic fluorometric procedure 1 ; at 25# C with use of a Turner III fluorometer G. K. Turner Associates, Palo Alto, Calif. 94303 ; equipped with a temperaturestabilized sample compartment. Sera were examined freshly or after storage at -15# C. Heat inactivation was assessed after exposure of sera to 56# C0.5 for 10 min. Time and temperature were controlled by a ; using 20O-el capacity capillary tubes to contain the serum aliquot, b ; placing the capillaries next to the thermometer in a waterfilled tube held in a serologic waterbath, c ; observing the thermometer continuously during the 10 mm, d ; cooling the specimens under running cold water immediately after heating, and e ; be and viread.
All patients should have been issued with a new peak flow meter since the measuring standard was changed to an EU scale in 2005. Standard range meters are suitable for use by adults and children. Low range meters should be used by those with severely restricted airflow.
Department of Pharmacology and Toxicology, University of Florence, 50134 Florence, Italy and * Department of Food Technology and Microbiology, University of Milan, 20133 Milan, Italy tinal content, resulting from the fermentation of car bohydrates and fibers in the colon, might be involved in protection against colon cancer 3, 4 ; . However, experimental studies using rats are inconclusive, neither confirming 5 ; nor refuting 6 ; the protective effect of lower pH on colon carcinogenesis by 1, 2-dimethylhydrazine DMH ; . Colonie proliferation has been suggested as a pos sible link between carbohydrate intake and carcino genesis 7 ; . We previously demonstrated that a diet high in cornstarch decreased colonie proliferation in mice 8 ; and that this effect was shared by different complex carbohydrates 9 ; . Moreover, high colonie proliferation was shown to be positively correlated with a high incidence of colon cancer in human popu lations 10 ; . Human studies have also demonstrated that pa tients with colonie adenomas, in comparison with controls, have a very efficient absorption of starch, thus reducing the amount of undigested carbohy drates reaching the cecum 11 ; . Carbohydrates can be fermented in the colon of most species, leading to the formation of short-chain fatty acids SCFA ; 12 ; , which have a series of interesting cellular effects. Experiments in vitro indicated that butyrate decreases proliferation and increases differentiation in different cell unes 13 ; . A diet rich in complex carbohydrates, particularly the poorly digestible carbohydrates, in creases the total output of cecal SCFA in rats 14, 15 ; . The relative percentage of SCFA may also have im portant effects, - patients with colon cancer have a higher percentage of acetate and a lower percentage of butyrate in the colon, compared with normal subjects 16 and vistaril.
Results First step: Oral vinorelbine 80 mg m2 weekly Patient characteristics A total of 82 patients were recruited in the two first phase II studies from March 1996 to June 1997. Fortyseven chemotherapy-naive patients with stage IIIB-IV NSCLC and 35 first-line patients with ABC were enrolled. The main characteristics of the two groups of patients with NSCLC and ABC, respectively ; are shown in Table 1. The median age of the overall population was 66.5 years and 72% had PS 1 or The majority of patients with ABC had received prior radiotherapy and 14 of 35 40% ; had received prior adjuvant chemotherapy, whereas a few patients with NSCLC 4% ; had received prior radiotherapy and none had received chemotherapy.
Coming to determine effective drugs and practice settings in positions that vinorelbine vinorelbine and vivelle.
Fortifier, fixer, colorer, embellir les cheveux, colorants et dcolorants. Bougies pour l'clairage ; bougies parfumes. Dsodorisants d'ambiance autres qu' usage personnel. Brleparfums. Date de priorit de production: 17 septembre 2004, pays: FRANCE, demande no: 04 3 314 en liaison avec le mme genre de marchandises. Emploi projet au CANADA en liaison avec les marchandises. The right to the exclusive use of YVES ROCHER and EXTRAITS DE FLEURS DE TIAR is disclaimed apart from the trade-mark. WARES: Soaps, namely: personal soaps, shaving soaps, perfumed soaps, hand soaps and moisturizing soaps. Personal deodorants, namely: spray, cream, roll-on, stick, anti-perspirant deodorants. Perfumery products for cosmetic use, namely: perfumes, colognes, eau de toilette, fresh water. Scent products for the home, namely: scented sprays for the home, scented wicks, scented stones, incense, scented woods for the home, scented pot-pourris, scented candles. Products for imparting scent to clothing, namely: scented sachets and waters for clothing, scented waters for ironing. Essential oils for personal use, namely: bath essences, fragrance oils, oils for aromatherapy, essential oils in the form of sticks, salts and powder. Cosmetics in all administration forms not for medical use, namely: tablets, gelcaps, yeast, ampules, syrups and sprays for cosmetic use for the care and beauty of the skin, for moisturizing and protecting the skin against aging, for preparing and accelerating a suntan, for extending the life of a suntan, for care of the hair and nails. Cosmetics for the care of the body and the face, namely: products for moisturizing, purifying, cleansing, toning, matting and improving the appearance of the body and the face in the form of creams, gels, emulsions, lotions, toners, mousses, masks and oils for skin care; in the form of creams, gels, lotions, toners and oils for suppressing wrinkles and combatting aging; in the form of exfoliant creams and gels; in the form of lotions, milks and gels for removing make-up; in the form of slimming creams, gels, lotions and oils; in the form of moisturizing, cleansing and refreshing towelettes; in the form of patches; lotions, emulsions, oils and creams for massage use; creams, oils, milks, lotions, mousses, salts and gels for the bath and shower; shaving creams, foams and gels; after-shave creams; pre- and after-shave sprays, emulsions, balms and lotions. Products for the care of feet and hands, namely: preparations for moisturizing, cleansing, relieving, relaxing, massaging and beautifying feet and hands, specifically: towelettes, gels, creams, oils, milks, balms and lotions for the hands and feet. Dentifrices. Products for the maintenance, beautification and treatment of nails, namely: nail polish and nail polish remover, nail polish undercoat, nail polish; treatment to smooth, nourish and harden nails, specifically: lotions, creams, gels, balms, oils, nail polishes. Sun and after-sun beauty products for cosmetic use, namely: creams, milks, lotions, oils, towelettes, sprays and gels. Cosmetics for make-up, namely: smoothing fixers for the eyelids, eyeliners, eyeshadow, mascaras, Kohl pencils, eyeliner pens, concealers in stick, cream or liquid form, make-up foundation, coloured creams, face powder, blush, lipstick, lip liners, eyebrow pencils, lip liner pens, lip gloss, smoothing fixers for the lips. Hair treatment, care and beautification products for cosmetic use, namely: gels, creams, shampoos, sprays, mousses, oils, masks, milks, lotions, to.
Be provided to participants for their research projects after they complete the course. Meeting of the Scientific Advisory Group, 89 May 2000 There are plans also for collaboration in research studies, including proposals on prevention of STIs, postabortion morbidity and strategies for prevention. The next meeting, scheduled for 89 May 2000, will bring together again HRP' SWG and the EURO-supported SAG. The two Groups did not meet in 1999. Development of a reproductive health strategy for Eastern Europe Another area proposed for collaboration is to provide assistance to countries in the region in developing policy and programmes in reproductive health including the development of a regional sexual and reproductive health strategy. Reproductive health strategies being employed in other regions could serve as a model. A request for supporting a consultant and dissemination workshop has been received from EURO. Dissemination of antenatal care ANC ; trial results to Eastern European policy-makers The Department is being requested to provide technical and financial support to EURO for a dissemination and voriconazole.
An angiotensin system blocker. Predisposing characteristics included age, gender, race, and whether a member previously used any antihypertensive medications other than ACEIs and ARBs. Because race is not available in claims data, it was controlled on an aggregate level using percentage of people who reported their race as white only in a member's Zip Code area based on the Census 2000 data.45 Other antihypertensives included diuretics General Product Indentifier Code beginning 37 ; , beta-blockers 33 ; , calcium channel blockers 34 ; , antiadrenergic antihypertensives 3620 ; , aldosterone receptor blockers 3625 ; , direct vasodilators 364000 ; , and antihypertensive combinations 3699 ; without ACEIs and ARBs. Enabling resources included residence urban, rural, or super rural income; number of unique medications in prior 6 months; number of doctor visits from July 1, 2003 to the end of 2004; initial therapeutic class ACEIs or ARBs utilization of mail-order service at any time during follow-up; presence of a yearly out-of-pocket maximum in member's pharmacy benefits; and whether a member used any antidepressant medications: mirtazapine GPI code 580300 ; , trazodone 58120080 ; , monoamine oxidase inhibitors 581000 ; , selective serotonin reuptake inhibitors SSRIs, 581600 ; , serotonin norepinephrine reuptake inhibitors SNRIs, 581800 ; , tricyclic agents 582000 ; , and miscellaneous antidepressants 583000 ; in the prior 6 months. Tricyclic agents were not coded as antidepressant medications in those members with a diagnosis of diabetes as these drugs are often used for diabetic neuropathy. Zip Codes were used to classify members as living in an urban, rural, or super rural area according to the Medicare ambulance fee schedule of the Center for Medicare and Medicaid Services CMS ; .46 A rural area is defined as an area outside a Metropolitan Statistical Area MSA ; or a New England County Metropolitan Area, or an area within an MSA identified as rural using the Goldsmith modification.47 A super rural area is defined as a rural area determined by the Secretary of Housing and Urban Development to be in the lowest 25th percentile of all rural population arrayed by population density.48 An area that is not classified as a rural or super rural area is considered an urban area. Income was also controlled on an aggregate level using household median income in a member's Zip Code area based on the Census 2000 Data.45 Need factors controlled for included conditions that angiotensin system blocking medications are generally used to treat or conditions associated with treatment. These conditions were based on the International Classification of Diseases, Ninth Revision, Clinical Modification ICD-9-CM ; diagnosis and procedure codes recorded in medical claims between July 1, 2003 and December 31, 2004. Diagnoses included essential hypertension ICD9-CM 401.xx ; , myocardial infarction 410.xx, 411.0x, 412. xx, 414.8x, 429.7x ; , congestive heart failure 398.91, 402.01, 402.11.
198. Adams DJ, Knick VC. MDR and non-MDR forms of cellular resistance to 5' noranhydrovinblastine Navelbine. Proceedings of the 83rd Annual Meeting of the American Association for Cancer Research; 1992 May 2023; San Diego, CA, USA. Philadelphia, PA: AACR; 1992. p. 462. 199. Adenis A, Vanlemmens L, Fournier C, Hecquet B, Bonneterre J. Mitoxantrone DHAD ; and vinorelbine VNR ; as a primary treatment of locoregional breast cancer BC ; [meeting abstract]. Proceedings of the 86th Annual Meeting of the American Association for Cancer Research; 1995 Mar 1822; Toronto, Canada. Philadelphia, PA: AACR; 1995. A253. 200. The efficacy and tolerance of Navelbine in the treatment of breast cancer metastases. Concours Med 1991; 113: 1508. Vinorelbine paclitaxel combination studied in treatment of metastatic breast cancer patients. Oncology Huntingt ; 1995; 9: 518, Ibrahim N, Hortobagyi GN, Valero V, Dhingra K, Willey J, Hohneker J, et al. Phase I study of vinorelbine NVB; Navelbine ; and paclitaxel PTX ; by simultaneous sim ; 3-hr infusion inf ; for untreated metastatic breast cancer MBC ; [meeting abstract]. Proceedings of the 86th Annual Meeting of the American Association for Cancer Research; 1995 Mar 1822; Toronto, Canada. Philadelphia, PA: AACR; 1995. A1443. 203. Navelbine in the treatment of bronchial and breast carcinoma. Onkologie 1996; 2: 1967. Oral vinorelbine promising and well tolerated in patients with advanced breast cancer. Oncology Huntingt ; 1997; 11: 255. Ardavanis A, Pissakas G, Missitzis I, Armonis B, Pateras C, Bousboukea A, et al. Multidisciplinary therapy of locally advanced breast cancer LABC ; with an induction chemotherapy combination of fluorouracil, epirubicin and vinorelbine FEN ; followed by surgery and postoperative chemoradiotherapy: an ongoing Phase II study [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 1518; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A485. 206. Barni S, Ionta MT, Battelli T, Ardizzoia A, Schieppati G, Frontini L, et al. L-PEV: a very challenging and active chemotherapy regimen in locally advanced breast cancer LABC ; [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 1518; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A331 and vortex.
Spain Blanco 2002 ; analysed the decision to retire early in Spain, focusing on whether the trend towards earlier retirement in Spain reflects individual preferences for leisure, or whether it can be ascribed to incentives in the tax-benefit system. She found evidence suggesting that the early retirement decision of disabled individuals in Spain is related to the financial incentives provided by the system, and that self-employed individuals use the disability insurance system to bring their retirement forward. The results found by Boldrin and Jimnez-Martn 2002 ; , who evaluated Spanish pension expenditure under alternative reform scenarios, more or less contradict these findings. For all the reforms they have considered, the financial impact of the mechanical effect appears to be larger than the behavioural impact. The reason for this finding is that the underlying behavioural model that is intended to map changes in financial incentives into changes in retirement patterns, explains a very small proportion of the measured variability in actual retirement behaviour: and, of that small portion, the part which is captured by the financial incentives is just a fraction. Hence, according to Boldrin and Jimnez-Martn, financial incentives do not seem to make much of a difference. However, they do suggest that a three-year reform may have an impact that is quite strong. Sweden Skogman Thoursie 1999 ; has investigated whether or not economic incentives affect the probability that a disability pension will be granted. He used a sample from the Swedish Level of Living Survey and estimated a reduced-form conditional logit model. The difference between the predicted income from disability insurance and the predicted income from labour was used as a measure of economic incentives. The results showed that a gain in predicted income from disability insurance relative to income from labour increases the probability that a worker will exit the labour market with a disability pension. The interpretation of the result is that economic incentives do in fact affect the numbers of people drawing new disability pensions. Wadensj and Palmer 1996 ; compare disability policies in Sweden and the Netherlands. Both countries have generous disability programs, which provide major pathways to early exit from the labour market. Despite the similarities, there is a higher labour force participation rate among older workers in Sweden than in the Netherlands. The authors point to some peculiarities in the Swedish labour market and disability policies that might account for the different outcomes. Among these distinctive features are the emphasis on the `work principle' in Swedish social and labour market policy, the low unemployment rates, the possibilities in Sweden of combining work and pensions through partial benefits, and the vocational rather than medical focus of rehabilitation policy. Palme and Svensson 2002a, 2002b, and 2003 ; have examined the effects of economic incentives inherent in pension schemes and income security programmes on retirement behaviour in the Swedish labour market in combination with the effects of variables for the workers' economic situation, education level, socio-economic group, family income, and county of residence ; . They used social security wealth and three alternative measures of accrual one-year benefit accrual, peak value, and option value ; . The social security system, occupational pensions, and insurance on the labour market--i.e. unemployment, sickness, and disability insurance--were considered. They estimated a model using panel and vinorelbine.
Underlying them. An example of such a matrix is shown in Figure 2. The incremental cost per QALY for docetaxel compared with paclitaxel is 1, 995, and the evidence underlying this estimate falls into category I. According to the matrix in Figure 2, docetaxel would be classified as `strongly recommended'. Again, this suggests that docetaxel provides good value for money compared with paclitaxel in this setting. Similarly, as the incremental cost per QALY of docetaxel compared with vinorelbine is 14, 055, and as this estimate was based on data from a randomised controlled trial category I evidence ; , according to Figure 2, docetaxel would again be classified as `strongly recommended'. Once more, this suggests that docetaxel provides good value for money compared with vinorelbine in this setting and vytorin.
Gastrointestinal: abdominal pain, anorexia, constipation, duodenal ulcer, esophagitis, gastrointestinal hemorrhage, gastrointestinal perforation, ischemic colitis, colitis, intestinal obstruction, ileus, neutropenic enterocolitis and dehydration as a consequence to gastrointestinal events have been reported. Hematologic: bleeding episodes. Disseminated intravascular coagulation DIC ; , often in association with sepsis or multiorgan failure, has been reported. Very care cases of acute myeloid leukemia and myelodysplasic syndrome have been reported in association with TAXOTERE when used in combination with other chemotherapy agents and or radiotherapy. Hypersensitivity: rare cases of anaphylactic shock have been reported. Very rarely these cases resulted in a fatal outcome in patients who received premedication. Hepatic: rare cases of hepatitis, sometimes fatal primarily in patients with pre-existing liver disorders, have been reported. Neurologic: confusion, rare cases of seizures or transient loss of consciousness have been observed, sometimes appearing during the infusion of the drug. Ophthalmologic: conjunctivitis, lacrimation or lacrimation with or without conjunctivitis. Excessive tearing which may be attributable to lacrimal duct obstruction has been reported. Rare cases of transient visual disturbances flashes, flashing lights, scotomata ; typically occurring during drug infusion and in association with hypersensitivity reactions have been reported. These were reversible upon discontinuation of the infusion. Hearing: rare cases of ototoxicity, hearing disorders and or hearing loss have been reported, including cases associated with other ototoxic drugs. Respiratory: dyspnea, acute pulmonary edema, acute respiratory distress syndrome, interstitial pneumonia. Pulmonary fibrosis has been rarely reported. Rare cases of radiation pneumonitis have been reported in patients receiving concomitant radiotherapy. Renal: renal insufficiency. 7. DRUG INTERACTIONS There have been no formal clinical studies to evaluate the drug interactions of TAXOTERE with other medications. In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin. Caution should be exercised with these drugs when treating patients receiving TAXOTERE as there is a potential for a significant interaction. 8. USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Pregnancy Category D. [see Warnings and Precautions 5.7 ; ] 8.3 Nursing Mothers It is not known whether TAXOTERE is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from TAXOTERE, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. 8.4 Pediatric Use The safety and effectiveness of docetaxel in pediatric patients have not been established. 8.5 Geriatric Use In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy in elderly patients. In a study conducted in chemotherapy-nave patients with NSCLC TAX326 ; , 148 patients 36% ; in the TAXOTERE + cisplatin group were 65 years of age or greater. There were 128 patients 32% ; in the vinorelbine + cisplatin group 65 years of age or greater. In the TAXOTERE + cisplatin group, patients less than 65 years of age had a median survival of 10.3 months 95% CI: 9.1 months, 11.8 months ; and patients 65 years or older had a median survival of 12.1 months 95% CI : 9.3 months, 14 months ; . In patients 65 years of age or greater treated with TAXOTERE + cisplatin, diarrhea 55% ; , peripheral edema 39% ; and stomatitis 28% ; were observed more frequently than in the vinorelbine + cisplatin group diarrhea 24%, peripheral edema 20%, stomatitis 20% ; . Patients treated with TAXOTERE + cisplatin who were 65 years of age or greater were more likely to experience diarrhea 55% ; , infections 42% ; , peripheral edema 39% ; and stomatitis 28% ; compared to patients less than the age of 65 administered the same treatment 43%, 31%, and 21%, respectively ; . When TAXOTERE was combined with carboplatin for the treatment of chemotherapy-nave, advanced non-small cell lung carcinoma, patients 65 years of age or greater 28% ; experienced higher frequency of infection compared to similar patients treated with TAXOTERE + cisplatin, and a higher frequency of diarrhea, infection and peripheral edema than elderly patients treated with vinorelbine + cisplatin. Of the 333 patients treated with TAXOTERE every three weeks plus prednisone in the prostate cancer study TAX327 ; , 209 patients were 65 years of age or greater and 68 patients were older than 75 years. In patients treated with TAXOTERE every three weeks, the following TEAEs occurred at rates 10% higher in patients 65 years of age or greater compared to younger patients: anemia 71% vs. 59% ; , infection 37% vs. 24% ; , nail changes 34% vs. 23% ; , anorexia 21% vs. 10% ; , weight loss 15% vs. 5% ; respectively. In the adjuvant breast cancer trial TAX316 ; , TAXOTERE in combination with doxorubicin and cyclophosphamide was administered to 744 patients of whom 48 6% ; were 65 years of age or greater. The number of elderly patients who received this regimen was not sufficient to determine whether there were differences in safety and efficacy between elderly and younger patients. Among the 221 patients treated with TAXOTERE in combination with cisplatin and fluorouracil in the gastric cancer study, 54 were 65 years of age or older and 2 patients were older than 75 years. In this study, the number of patients who were 65 years of age or older was insufficient to determine whether they respond differently from younger.
Phase II trial of oral vinorelbine in combination with capecitabine, and trastuzumab as first-line therapy in women with previously untreated HER2 positive metastatic breast cancer. Women with advanced breast cancer and whose tumour is HER2 positive are offered an oral version of the chemotherapy drugy Navelbine as well as Herceptin. Colorectal: Randomised phase III trial of De Gramont schedule 5-fluorouracil and leucovorin plus irinotecan versus single agent irinotecan, for people with previously treated metastatic colorectal cancer. Patients receive either irinotecan alone or in combination to treat metastatic colorectal cancer. The MAX study: A randomised phase II III study to evaluate the role of mitomycin C, avastin and xeloda in patients with metastatic colorectal cancer Protocol number: AG0501CR ; . Patients are offered a new treatment option for their metastatic disease. Randomised phase II trial of irinotecan with hyaluronan HYCAMP ; versus irinotecan as treatment for patients with metastatic colorectal cancer who have failed 5-FU based chemotherapy. Gastric: A randomised phase II study evaluating a weekly schedule of docetaxel with cisplatin and 5-FU wTCF ; or with capecitabine wTX ; in advanced oesophago-gastric cancer. In this study patients are offered one of two new treatments for their disease. Chronic lymphocytic leukemia: An open-label, multicentre, randomised, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide FCR ; versus fludarabine and cyclophosphamide alone FC ; in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia CLL ; . In this study, patients have the possibility of receiving the new compound rituximab in addition to standard treatment for their CLL. Phase III trial of combined immunochemotherapy with fludarabine, cyclophosphamide and rituximab FC-R ; versus chemotherapy with fludarabine and cyclophosphamide FC ; alone in patients with previously untreated chronic lymphocytic leukaemia CLL8 Protocol number ML17102 ; . In this study patients who have not previously been treated for CLL have the possibility of receiving rituximab in addition to standard treatment for their disease. Lung cancer: A randomised, double blind, placebocontrolled study of subjects with previously untreated extensive-stage small-cell lung cancer SCLC ; treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa. Patients who are anaemic prior to treatment for SCLC receive etoposide placebo to assist their production of red blood cells and abraxane.
|
Copyright © 2007 by Buying.fizwig.com Inc.
